Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Share
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Erica York, Tax Foundation senior economist, joins ‘Squawk Box’ to discuss the foundation’s tax policy tracker, where each 2024 presidential candidate stands on taxes, and more.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Street Signs Angel Gurria, secretary general of the OECD, discusses U.S.-China trade, multilateralism and digital taxes. 06:25 Tue, Jan 21 20208:41 AM EST
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Matt Bryson of Wedbush Securities joins ‘TechCheck’ to discuss the swelling supply of semiconductors, bullish picks for the chip sector and the outlook for chip providers in gaming. 04:32 Tue, Dec 27 202212:08 PM EST
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell CNBC’s Leslie Picker joins ‘Closing Bell’ to report on BlackRock’s plan to cut 3% of it’s global workforce. 01:27 Tue, Jan 9 20244:59 PM EST
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Kutgun Maral of RBC Capital Markets and Doug Creutz of Cowen join ‘The Exchange’ to discuss streaming stocks like Netflix, Paramount Global and Disney. 07:44 Mon, Jul 18 20221:58 PM EDT
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Fred Thiel, Marathon Digital CEO and Mike Belshe, Bitgo CEO, joins ‘Closing Bell Overtime’ to talk the kick off of spot bitcoin ETF trading after SEC approval.